C. Bouchet et al., PROGNOSTIC VALUE OF UROKINASE PLASMINOGEN-ACTIVATOR IN PRIMARY BREAST-CARCINOMA - COMPARISON OF 2 IMMUNOASSAY METHODS, British Journal of Cancer, 77(9), 1998, pp. 1495-1501
Urokinase-type plasminogen activator (uPA) is a potentially important
prognostic factor in breast cancer for identifying patients at high ri
sk of recurrence. This retrospective study assessed two enzyme-linked
immunosorbent assay (ELISA) methods measuring uPA antigen levels in 49
9 primary breast cancer cytosols. Both uPA methods were applied to cyt
osols used routinely for oestrogen (ER) and progesterone (PgR) recepto
r assays. uPA was determined using a classical ELISA method (Imubind;
American Diagnostica) and a novel automatic immunoluminometric assay (
Lia; Sangtec Medical). The uPA Imubind method revealed about twice as
much uPA antigen (median 0.75 ng mg(-1) protein) as the uPA Lia method
(median 0.38 ng mg(-1) protein). The correlation coefficient between
the two methods was acceptable (r = 0.81), but the two techniques are
not interchangeable. Univariate analyses confirmed the poor outcome of
patients whose tumours contained large amounts of uPA, regardless of
the technique used. Multivariate analyses showed that uPA Imubind and
uPA Lia values were both strong independent prognostic factors.